|Articles|October 14, 2019
Characterization and Formulation Screening of mAb and Antibody-Drug Conjugates (ADCs) by High-throughput DLS
Author(s)Wyatt
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
New $82 Million Biopharma Launch Targets Rare Disease Development With AI-Driven Strategy
2
WHO Finalizes United States’ Withdrawal from Organization: Report
3
GSK’s Arexvy Gains EU Approval for Adults Aged 18 Years and Older
4
Green Chemistry’s Role in Advancing US Chemical Innovation
5